Showing results (401-410 of 422) with videos related to

Sort By:
Pageof 43
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinF Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.
Oral Oncology|November 10, 2025
Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancerRose Doerfler, Jie Chen, Carl Kim, et al.
Nature Communications|July 2, 2026
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 yearsClaus Garbe, Ulrike Keim, Teresa Amaral, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Integrating Artificial Intelligence-Driven Digital Pathology and Genomics to Establish Patient-Derived Organoids as a Novel Alternative Model for Drug Response in Head and Neck CancerRose Doerfler, Jie Chen, Carl Kim, et al.
Research Square|August 30, 2023
Tumor cell p38 inhibition to overcome immunotherapy resistanceJason J Luke, Rebekah E Dadey, Ryan C Augustin, et al.
Lancet (London, England)|April 3, 2022
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trialJason J Luke, Piotr Rutkowski, Paola Queirolo, et al.
Cancer Research Communications|November 26, 2025
Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid TumorsBenjamin T Cooper, Wade T Iams, David B Page, et al.
Research Square|December 23, 2024
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancersBrandon M Lehrich, Evan R Delgado, Tyler M Yasaka, et al.
Nature Medicine|October 19, 2023
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialJason J Luke, Manish R Patel, George R Blumenschein, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2021
Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variantsAmarendra Pegu, Sarah O'Connell, Stephen D Schmidt, et al.
Pageof 43